The DOI matches its Crossref record; 1,173 of the 1,177 references it cites were found in a registry or an index.
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Open accessAbstract
AIM: The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease” provides an update to and consolidates new evidence since the “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease” and the corresponding “2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease.” METHODS: A comprehensive literature search was conducted from September 2021 to May 2022. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: This guideline provides an evidenced-based and patient-centered approach to management of patients with chronic coronary disease, considering social determinants of health and incorporating the principles of shared decision-making and team-based care. Relevant topics include general approaches to treatment decisions, guideline-directed management and therapy to reduce symptoms and future cardiovascular events, decision-making pertaining to revascularization in patients with chronic coronary disease, recommendations for management in special populations, patient follow-up and monitoring, evidence gaps, and areas in need of future research. Where applicable, and based on availability of cost-effectiveness data, cost–value recommendations are also provided for clinicians. Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Biomarkers such as elevated blood pressure, lipid levels, and inflammatory markers are closely associated with CVD risk, and treatments that reduce these markers can reduce CVD risk in populations with and without diabetes [11–13].”
From Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lifestyle intervention, including weight loss in people with overweight or obesity (when appropriate) (19,92), increased physical activity, and medical nutrition therapy, allows some individuals to reduce ASCVD risk factors.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Lifestyle intervention, including weight loss in people with overweight or obesity (when appropriate) (22,86), increased physical activity, and medical nutrition therapy, allows some individuals to reduce ASCVD risk factors such as hypertension, dyslipidemia, or obesity.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [86]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“BP was measured using a calibrated mercury sphygmomanometer by trained medical interns, who underwent standardized training in proper BP measurement techniques, as per American Heart Association (AHA) guidelines [15].”
From Prevalence of Undiagnosed Hypertension in Young Adults: A Community-Based Study (2025) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Research works printed but not linked: 142
- 10.1161/CIR.0000000000000042 · DOI · Paper page
- Wright, RS, Anderson, JL, Adams, CD, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:e426–e579.
- 10.1161/cir.0b013e318277d6a0 · DOI · Paper page
- 10.1161/cir.0b013e318277d6a0 · DOI · Paper page
- 10.1161/CIR.0000000000001029 · DOI · Paper page
- 10.1161/CIR.0000000000001038 · DOI · Paper page
- 10.1056/NEJMoa0805796 · DOI · Paper page
- 10.1001/jamacardio.2019.0035 · DOI
- 10.1056/NEJMoa070829 · DOI · Paper page
- 10.1056/NEJMoa1915922 · DOI · Paper page
- 10.1056/NEJMoa0805796 · DOI · Paper page
- 10.1161/CIRCOUTCOMES.118.005079 · DOI
- Gulati, M, Levy, PD, Mukherjee, D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18–e114.
- 10.1056/NEJMoa1916370 · DOI · Paper page
- 10.1161/01.CIR.0000072790.23090.41 · DOI · Paper page
- 10.1093/eurheartj/ehq500 · DOI · Paper page
- 10.1007/BF03007355 · doi:10.1007/bf03007355
- 10.1007/s12350-012-9548-3 · DOI
- 10.1093/ehjci/jez258 · DOI
- 10.1161/CIR.0000000000000095 · DOI · Paper page
- 10.1056/NEJMoa070829 · DOI · Paper page
- 10.1056/NEJMoa1915922 · DOI · Paper page
- 10.1056/NEJMoa1916370 · DOI · Paper page
- 10.1161/CIR.0000000000000678 · DOI · Paper page
- Institute of Medicine. Health Literacy: A Prescription to End Confusion. The National Academies Press; 2004
- 10.1001/archinte.1996.00440120070006 · doi:10.1001/archinte.1996.00440120070006 · Paper page
- 10.1161/CIR.0000000000000678 · DOI · Paper page
- 10.1016/j.jacc.2015.03.550 · DOI
- 10.1161/CIR.0000000000000678 · DOI · Paper page
- 10.1161/CIR.0000000000001078 · DOI · Paper page
- 10.1161/CIR.0000000000000462 · DOI · Paper page
- 10.1161/CIR.0000000000000766 · DOI · Paper page
- Bhatti, JS, Kaur, S, Bhatti, GK, et al. Genetic susceptibility of vitamin D receptor (VDR) gene variants (BsmI, TaqI and FokI) to coronary artery disease in Asian Indians. Endocr Pract. 2019;25:6A.
- 10.1161/CIR.0000000000000019 · DOI · Paper page
- 10.1001/jama.289.23.3106 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.119.041914 · DOI
- Babb S Malarcher A Schauer G et al. Quitting smoking among adults - United States 2000-2015. 2017. 1545-861X (Electronic) 0149-2195. Accessed Jan 6 2021. https://www.ncbi.nlm.nih.gov/pubmed/28056007.
- 10.1161/CIR.0000000000000678 · DOI · Paper page
- 10.1016/j.jacc.2018.10.027 · DOI · Paper page
- 10.1161/CIR.0b013e3182447787 · DOI · Paper page
- Rana, JS, Virani, SS, Moffet, HH, et al. Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification. Am J Med. 2021
- 10.1161/CIR.0000000000000042 · DOI · Paper page
- Institute for Clinical and Economic Review. Alirocumab for treatment of high cholesterol: effectiveness and value: new evidence update. 2019. Accessed March 1 2022. https://icer.org/wp-content/uploads/2020/10/ICER_Alirocumab_Final_NEU_021519.pdf.
- 10.1161/CIR.0000000000000625 · DOI · Paper page
- 10.1161/CIR.0000000000000456 · DOI · Paper page
- Lin GA Kazi D DS Jih J et al. Inclisiran and bempedoic acid for patients with heterozygous familial hypercholesteremia and for secondary prevention of ASCVD: effectiveness and value; final evidence report. Institute for Clinical and Economic Review; 2021. Accessed March 1 2022. https://icer.org/wp-content/uploads/2020/10/ICER_High-Cholesterol_Final-Evidence-Report_030221.pdf.
- Appel, LJ, Champagne, CM, Harsha, DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083–2093.
- 10.1056/NEJM200101043440101 · DOI · Paper page
- 10.1016/S0140-6736(04)16980-8 · DOI · Paper page
- 10.1161/HYP.0000000000000065 · DOI · Paper page
- 10.1161/cir.0b013e318277d6a0 · DOI · Paper page
- 10.1161/CIR.0000000000000095 · DOI · Paper page
- 10.1161/HYP.0000000000000018 · DOI · Paper page
- 10.1161/CIR.0b013e31821daaf6 · DOI · Paper page
- 10.1161/CIR.0000000000001063 · DOI · Paper page
- 10.1016/j.jacc.2020.05.037 · DOI · Paper page
- 10.1161/01.cir.0000437739.71477.ee · DOI · Paper page
- 10.1056/NEJMoa1603827 · DOI · Paper page
- 10.1056/NEJMoa1607141 · DOI · Paper page
- 10.1056/NEJMoa1915922 · DOI · Paper page
- 10.1056/NEJMoa070829 · DOI · Paper page
- 10.1161/CIR.0000000000000564 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.106.180945 · DOI
- 10.1161/CIR.0000000000001063 · DOI · Paper page
- 10.1136/heartjnl-2017-312832 · DOI · Paper page
- 10.1161/01.CIR.0000121360.31954.1F · DOI · Paper page
- 10.1177/2047487314561168 · DOI · Paper page
- 10.1161/CIR.0000000000000749 · DOI · Paper page
- Dibben, G, Faulkner, J, Oldridge, N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2021;11:CD001800.
- 10.1371/journal.pone.0177658 · DOI
- 10.1161/CIR.0000000000000931 · DOI · Paper page
- Feres, F, Costa, RA, Abizaid, A, et al. Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents: The OPTIMIZE Randomized Trial. JAMA. 2013;310:2510–2522.
- 10.1161/CIRCULATIONAHA.120.050304 · DOI
- 10.1016/j.jacc.2020.09.011 · DOI · Paper page
- 10.1161/CIR.0000000000000651 · DOI
- 10.1161/CIR.0000000000001038 · DOI · Paper page
- 10.1136/bmj.324.7329.71 · DOI · Paper page
- 10.1093/eurheartj/ehz425 · DOI · Paper page
- 10.1161/JAHA.120.019017 · DOI
- 10.1001/jama.2012.12559 · DOI · Paper page
- 10.1161/CIR.0000000000001063 · DOI · Paper page
- 10.1161/CIR.0000000000001038 · DOI · Paper page
- 10.1161/CIR.0000000000000549 · DOI · Paper page
- 10.1161/CIR.0000000000000665 · DOI · Paper page
- 10.1161/cir.0b013e318277d6a0 · DOI · Paper page
- 10.1056/NEJM200001203420301 · DOI · Paper page
- 10.1161/CIR.0000000000001063 · DOI · Paper page
- Molad, Y, Reibman, J, Levin, KI, et al. A new mode of action for an old drug: colchicine decreases surface expression of adhesion molecules on both neutrophils (PMNs) and endothelium [abstract]. Arthritis Rheum. 1992;35(abstract):S35.
- 10.1093/eurheartj/ehy504 · DOI
- 10.1161/cir.0b013e318277d6a0 · DOI · Paper page
- 10.1056/NEJMoa1916370 · DOI · Paper page
- 10.1161/cir.0b013e318277d6a0 · DOI · Paper page
- 10.1161/CIR.0000000000001038 · DOI · Paper page
- 10.1161/CIR.0000000000000095 · DOI · Paper page
- 10.1056/NEJMoa1916370 · DOI · Paper page
- 10.1056/NEJMoa1100356 · DOI · Paper page
- 10.1056/NEJMoa1915922 · DOI · Paper page
- 10.1056/NEJMoa1205361 · DOI · Paper page
- 10.1161/CIR.0000000000001038 · DOI · Paper page
- 10.1056/NEJMoa1205361 · DOI · Paper page
- 10.1056/NEJMoa2206606 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.120.049755 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.117.031907 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.113.006689 · DOI · Paper page
- 10.1056/NEJMoa0804626 · DOI · Paper page
- 10.1056/NEJMoa2112299 · DOI · Paper page
- 10.1161/CIR.0000000000001038 · DOI · Paper page
- 10.1016/S0140-6736(16)32052-9 · DOI · Paper page
- Gallo, M, Blitzer, D, Laforgia, PL, et al. Percutaneous coronary intervention versus coronary artery bypass graft for left main coronary artery disease: a meta-analysis. J Thorac Cardiovasc Surg. 2020;S0022–5223(0020)30888-30886.
- 10.1161/CIRCULATIONAHA.109.911669 · DOI · Paper page
- Lee, KM, Kim, MH, Choi, SY, et al. Twelve versus 30 month dual antiplatelet therapy after percutaneous coronary intervention using national health insurance review & assessment (HIRA) database. Eur Heart J. 2016;37:667.
- 10.1056/NEJMoa1610227 · DOI · Paper page
- 10.1161/CIR.0000000000000564 · DOI · Paper page
- 10.1016/j.amjcard.2016.02.034 · DOI
- 10.1016/j.cjca.2016.01.009 · DOI
- 10.2340/20030711-1000001 · DOI
- 10.1161/CIR.0000000000001029 · DOI · Paper page
- 10.1161/CIR.0000000000001038 · DOI · Paper page
- 10.1016/j.jacc.2020.11.022 · DOI · Paper page
- 10.1161/CIR.0000000000001063 · DOI · Paper page
- 10.1161/CIR.0000000000000923 · DOI · Paper page
- 10.1161/CIR.0000000000001038 · DOI · Paper page
- 10.1136/heartjnl-2020-318119 · DOI
- 10.1161/CIR.0000000000001056 · DOI
- 10.1161/CIR.0000000000000772 · DOI · Paper page
- Bogana Shanmugam, V, Wong, DT, Rashid, H, et al. Bleeding outcomes after non-emergency percutaneous coronary intervention in the very elderly. J Geriatr Cardiol. 2017;14:624–631.
- 10.1016/j.jacc.2004.06.068 · doi:10.1016/j.jacc.2004.06.068 · Paper page
- 10.1161/CIR.0000000000001038 · DOI · Paper page
- 10.1056/NEJMoa1915925 · DOI · Paper page
- 10.1161/CIR.0000000000000695 · DOI · Paper page
- 10.1161/CIR.0000000000000625 · DOI · Paper page
- 10.1016/j.jacc.2021.06.011 · DOI · Paper page
- 10.1002/ehf2.12329 · DOI
- 10.1161/CIR.0000000000001038 · DOI · Paper page
- 10.1016/j.healun.2013.06.023 · DOI
- 10.1161/CIR.0000000000000456 · DOI · Paper page
- 10.1161/CIR.0000000000000456 · DOI · Paper page
- 10.1056/NEJMoa1915922 · DOI · Paper page
- 10.1136/openhrt-2020-001499 · DOI
- 10.18549/PharmPract.2015.02.575 · DOI
- 10.1186/s12933-015-0296-y · DOI · Paper page
- 10.1056/NEJMoa1916370 · DOI · Paper page
Cited by
Khan, S. S., Coresh, J., Pencina, M. J., Ndumele, C. E., Rangaswami, J., Chow, S. L., Palaniappan, L. P., Sperling, L. S., Virani, S. S., Ho, J. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001191 · Cited by 797
“Of note, this does not address or mitigate the importance of risk assessment and prevention in those with prevalent CVD (eg, secondary prevention, 18 stroke prevention in atrial fibrillation 19 ), in those with symptoms suggestive of CVD (eg, chest pain 20 ), or in selected patient subgroups…”
BackgroundSelf-citationGornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001251 · Cited by 771
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
Joynt Maddox, K. E., Elkind, M. S. V., Aparicio, H. J., Commodore-Mensah, Y., de Ferranti, S. D., Dowd, W. N., Hernandez, A. F., Khavjou, O., Michos, E. D., Palaniappan, L., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001256 · Cited by 374
Self-citation
Metadata
- Authors
- Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., Kazi, D. S., Kolte, D., Kumbhani, D. J., LoFaso, J., Mahtta, D., Mark, D. B., Minissian, M., Navar, A. M., Patel, A. R., Piano, M. R., Rodriguez, F., Talbot, A. W., Taqueti, V. R., Thomas, R. J., van Diepen, S., Wiggins, B., & Williams, M. S.
- Affiliations
- ACC/AHA representative.
- National Lipid Association (US)
- Preventive Cardiovascular Nurses Association representative.
- Former Joint Committee on Clinical Practice Guideline member; current member during the writing effort.
- Society for Cardiovascular Angiography and Interventions (US)
- Patient representative/lay stakeholder.
- American Society for Preventive Cardiology representative.
- AHA/ACC Joint Committee on Clinical Data Standards.
- American College of Clinical Pharmacy (US)
- AHA/ACC Joint Committee on Performance Measures.
- ORCID
- Virani, Salim S.
- Newby, L. Kristin
- Arnold, Suzanne V.
- Bittner, Vera
- Brewer, LaPrincess C.
- Demeter, Susan Halli
- Dixon, Dave L.
- Fearon, William F.
- Johnson, Heather M.
- Kazi, Dhruv S.
- Kolte, Dhaval
- Kumbhani, Dharam J.
- Mahtta, Dhruv
- Mark, Daniel B.
- Minissian, Margo
- Patel, Amit R.
- Piano, Mariann R.
- Taqueti, Viviany R.
- Thomas, Randal J.
- Wiggins, Barbara
- Williams, Marlene S.
- Venue
- Circulation
- Published
- 2023-08-29
- Volume
- 148
- Issue
- 9
- Pages
- e9-e119
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W4384922756
- Semantic Scholar
- dbf36eacb0a7064d1916de30aea602da0fd55bf2
- Cited by
- 1,598
- References
- 1,177
- Citations by year
- 2026: 535 · 2025: 584 · 2024: 416 · 2023: 63
- FWCI
- 426.88
- Type
- journal article
- Language
- en
- Update notices
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Circulation (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eCommons - AKU (Aga Khan University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Heart Association
- Office of Science
- National Heart, Lung, and Blood Institute (K01HL144607)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Keywords
- stable coronary artery disease, guideline-directed therapy, revascularization, shared decision-making, team-based care, social determinants of health, cardiovascular events, patient follow-up, cost-effectiveness
- MeSH terms
- American Heart Association, Cardiology, Coronary Disease, Humans, United States, Myocardial Ischemia, Proliferating Cell Nuclear Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. https://app.cochat.ai/papers/10.1161/cir.0000000000001168
- The paper
- Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., Kazi, D. S., Kolte, D., Kumbhani, D. J., LoFaso, J., Mahtta, D., Mark, D. B., Minissian, M., Navar, A. M., Patel, A. R., . . . Williams, M. S. (2023). 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. https://doi.org/10.1161/cir.0000000000001168
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.